Efficacy of uro-vaxom in recurrent infectious-inflammatory diseases of the urogenital system
- Authors: Kul'chavenya EV1, Breusov AA1, Kulchavenya EV1, Breusov AA1
-
Affiliations:
- Issue: No 4 (2011)
- Pages: 7-11
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279168
- ID: 279168
Cite item
Full Text
Abstract
Our study prospects of urovaxom in improvement of efficacy and prevention of recurrent urogenital infection. One capsule of oral vaccine uro-vaxom was given daily for a month to 127 patients: 23 males with chronic bacterial prostatitis/urethroprostatitis, 75 females with chronic cystitis, 29 females with urolithiasis complicated with secondary chronic pyelonephritis. Control examination was made each two months for a year. In signs of inflammation the patients received one more course of uro-vaxom for a month. It was followed by control examinations each three month for a year. We observed a 6-12 month "cold" period after one course of uro-vaxom in 86.7% patients. After the second course of immunoprophylaxis recurrent urogenital infection occurred 8 times less often. Thus, immunoprophylaxis of urogenital infection with oral vaccine uro-vaxom is highly effective, is well tolerated and, therefore, must enter the standards of medical care for patients with urogenital infection.
Keywords
References
- Naber K. G., Cho Y. H., Matsumoto Т., Schaeffer A. S. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int. J. Antimicrob. Agents 2009; 33(2): 111-119.
- Krieger J. N. Urinary tract infections: what's new? Urol. (Baltimore) 2002; 168: 2351-2358.
- Nicolle L. E. Asymptomatic bacteriuria in the elderly. Infect. Dis. Clin. N. Am. 1997; 11: 647-662.
- Kun Suk Kim, Ji-Yoon Kim, In Gab Jeong et al. A prospective Multi-center Trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis. J. Korean Med. Sci. 2010; 25: 435-439.
- Huber M., Krauter K., Winkelmann G. et al. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int. J. Immunopharmacol. 2000; 22: 1103-1111.
- Bauer H. W., Rahls W., Lauener P. A., Plessmann G. S. Prevention of recurrent urinary tract infections with immuno-active E. Coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int. J. Antimicrob. Agents 2002; 19(6): 451- 456.
- Schmidharnmer S., Ramoner R., Holtl L. et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urol. 2002; (3); 606: 521-526.
- Thilagarajah R., Witherow R. O., Walker M. M. Quantitative hystopathology can aid diagnosis in painful bladder syndrome. J. Clin. Pathol. 1998; 51: 211-214.
- Schulman C. C., Corbusier A., Michiels H., Taenzer H. J. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J. Urol. (Baltimore) 1993; 150: 917-921.
- Magasi P., Panovics J., Illes A, Nagy M. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomizes multicenter double-blind trial. Eur. Urol. 1994; 26: 137-140.
- Hachen H. J. Oral immunotherapy in paraplegic lpatients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J. Urol. (Baltimore) 1990; 143: 759-763.
- Tammen H. The German urinary tract infection study group. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. Br. J. Urol. 1990; 65: 6-9.
- Schneider H.-J. New therapeutic approach for recurrent urinary tract infections. Marked reduction in recurrence rate in women with uncomplicated cystitis - few side effects, high compliance. Allgemeinarzt 1990; 12: 626-633.
- Popa G., Lauber K.-D., Rothe H., Rugendorff E. Rezidivierende Harnwegsinfektionen in der Postmenopause. Wirksamkeit einer oralen Immuntherapie mit E. Coli-fraktionen. Münch. Med. Wschr. l996; 138: 713-716.
Supplementary files
